Oligonucleotide Synthesis Market Set to Reach US$ 18.04 Billion by 2033 as Scalable Manufacturing Supports Growing RNA Therapeutics Pipeline

The Oligonucleotide Synthesis Market size was at US$ 8.91 billion in 2025 and is expected to reach US$ 18.04 billion by 2033, growing at a CAGR of 9.0% during the forecast period 2026-2033.

The market is witnessing strong growth driven by increasing demand for oligonucleotide-based therapeutics, expanding applications in drug discovery and molecular diagnostics, and advancements in automated and large-scale synthesis technologies. Rising investments in precision medicine, gene therapies, and nucleic acid research are further supporting the adoption of oligonucleotide synthesis across pharmaceutical, biotechnology, and research applications.

Get a Sample PDF of this Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/oligonucleotide-synthesis-market?ram

United States: Key Industry Developments

✅ July 2026: LGC, Biosearch Technologies expanded its nucleic-acid chemistry offering with updated oligonucleotide synthesis and instrumentation catalogues, strengthening its end-to-end portfolio covering synthesis reagents and automated synthesizers.

✅ April 2026: Integrated DNA Technologies (IDT) expanded its Coralville, Iowa manufacturing footprint, increasing oligonucleotide synthesis capacity by more than threefold to support customized MRD and NGS oncology applications. The expansion improves production scale, flexibility and turnaround for high-quality oligonucleotides.

✅ January 2026: Integrated DNA Technologies (IDT) opened an expanded R&D and innovation center in Sunnyvale, California, targeting next-generation synthesis technologies, including novel chemistries, enzymatic synthesis and alternative synthesis platforms for high-throughput genomics applications.

Japan: Key Industry Developments

✅ November 2025: Astellas Pharma launched IzervayTM (avacincaptad pegol sodium) in Japan, an oligonucleotide-based C5 inhibitor for geographic atrophy associated with age-related macular degeneration, marking the commercialization of another therapeutic oligonucleotide in the Japanese market.

✅ October 2025: Ajinomoto Bio-Pharma Services announced a collaboration with Gene Tools to expand access to PMO therapeutics, leveraging Ajinomoto's oligonucleotide manufacturing capabilities and supporting broader development and supply of phosphorodiamidate morpholino oligomers.

✅ July 2025: FUJIFILM Wako Pure Chemical introduced Aminolinker PS, a non-swelling polystyrene solid support designed for chemical oligonucleotide synthesis, providing controlled particle and pore characteristics for applications requiring tailored synthesis scale, chain length and oligonucleotide quality.

Strategic Acquisitions & Partnerships

✅ KH Neochem entered into a business alliance with Hokkaido System Science (HSS) on July 15, 2026, under which HSS launched contract synthesis services for glycan-modified oligonucleotides using KH Neochem's glycan technologies. The partnership expands access to glycan-modified oligo synthesis and strengthens delivery-oriented nucleic-acid manufacturing capabilities.

✅ BioSpring GmbH and Luxna Biotech Co., Ltd. expanded their strategic XNA partnership on June 15, 2026, enabling BioSpring to manufacture custom next-generation oligonucleotides incorporating Luxna's GuNATM amidites, in addition to AmNATM, scpBNATM and 5′-CPTM chemistries. The expanded chemistry portfolio is intended to improve nuclease resistance, target binding and safety characteristics of therapeutic oligos.

Key Players:

Thermo Fisher Scientific Inc. | Agilent Technologies Inc. | Integrated DNA Technologies (IDT) | LGC Biosearch Technologies | Bio-Synthesis Inc. | GE Healthcare (Cytiva) | Eurofins Genomics | TriLink BioTechnologies | Merck KGaA (Sigma-Aldrich) | ATDBio Ltd.

Key Highlights: Top 5 Key Players in Oligonucleotide Synthesis Market 2026

-Thermo Fisher Scientific Inc.: Strengthened its oligonucleotide development and quality-control capabilities through integrated LC-MS workflows, low-adsorption LC technologies, high-resolution mass spectrometry, and advanced data-processing solutions supporting structural characterization, impurity profiling, metabolite identification, and GMP batch-release testing of oligonucleotide therapeutics.

-Agilent Technologies Inc.: Launched Agilent Advanced Therapeutics in March 2026, integrating its nucleic-acid capabilities with BIOVECTRA to provide scalable oligonucleotide development and manufacturing from discovery through clinical and commercial production. Agilent also introduced a new oligonucleotide analytical standard for LC-MS system qualification, supporting faster and more consistent analytical workflows.

-Integrated DNA Technologies (IDT): Expanded its Coralville, Iowa manufacturing footprint in April 2026, increasing oligonucleotide synthesis capacity by more than threefold to support growing demand for customized MRD and NGS-based oncology applications. The expansion also increased production capacity for oPoolsTM Oligo Pools and strengthened customization across labeling, concentration, formulation, yield, and delivery formats.

-LGC, Biosearch Technologies: Advanced high-performance oligonucleotide synthesis through its PrimeMaxTM CPG technology, featuring higher surface area and optimized loading designed to increase full-length oligo productivity and synthesis scale. Its 2026 technical work demonstrated a 40% productivity gain for 400 Å PrimeMax CPG in siRNA synthesis while supporting reduced material consumption.

-Eurofins Genomics: Expanded its oligonucleotide synthesis portfolio with new ordering and customization capabilities, including additional synthesis scales, LNA and PTO modifications, expanded RNA/chimeric options, aliquoting features, minimum-yield calculations, and HPSF/NGS-grade EXTREmer options. Its GMP manufacturing infrastructure also supports dedicated production streams for research-use and regulated oligonucleotide manufacturing.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oligonucleotide-synthesis-market?ram

Oligonucleotide Synthesis Market Opportunities

-Scaling RNA Therapeutics: Expanding synthesis capacity for rapidly advancing antisense oligonucleotide, siRNA, and other RNA-based therapeutic pipelines.

-Capturing Outsourced Manufacturing: Capitalizing on the shift toward specialized oligonucleotide CDMO services for development, GMP scale-up, analytical testing, and commercial manufacturing.

-Advancing Complex Oligo Design: Meeting rising demand for chemically modified and conjugated oligonucleotides, including LNA, phosphorothioate, and GalNAc-enabled designs.

-Accelerating Genomics & Diagnostics: Serving sustained demand for custom DNA/RNA oligos across PCR, sequencing, molecular diagnostics, gene editing, and research applications.

How We Build Trusted Market Research Reports:

Our analysis of the global Oligonucleotide Synthesis Market draws on a blend of primary research, including expert interviews and industry surveys, and secondary sources such as company filings, trade data, and regulatory records. The report examines the forces shaping the market today, from regulatory shifts and competitive dynamics to historical performance trends, while also tracking technological progress, product innovation, and developments in adjacent industries. Beyond current conditions, we assess where the market is headed, mapping growth opportunities, operational risks, and emerging challenges likely to influence its trajectory over the forecast period.

Regional Insights:

-North America: 40.4% (Largest share, supported by strong biotechnology and pharmaceutical activity, extensive genomics research, and high demand for oligonucleotides in research, diagnostics, and therapeutics).

-Europe: 29.1% (Second-largest share, supported by EU research funding, collaborative life-science initiatives, and established pharmaceutical and biotechnology infrastructure).

-Asia Pacific: 24.2% (Fastest-growing region, driven by expanding biotechnology infrastructure and increasing demand for synthetic nucleic acids; the region is projected to grow at a 17.9% CAGR through 2033).

-Latin America: 4.4% (Emerging market, supported by expanding biotechnology and research capabilities, with Brazil expected to remain the regional leader).

-Middle East & Africa: 2.0% (Smallest share, with growth supported by increasing biotechnology investments, research infrastructure, and demand for oligonucleotide-based diagnostics and therapeutics).

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=oligonucleotide-synthesis-market?ram

Market Segmentation Analysis:

-By Product Type: Synthesized Oligonucleotides Support Diverse Molecular Applications
Reagents include phosphoramidites, activators, oxidizers, capping and deblocking chemicals essential for chemical synthesis. Equipment includes automated oligonucleotide synthesizers and processing systems that enable controlled, scalable production. Synthesized oligonucleotides comprise custom DNA and RNA sequences, including modified and labeled oligos, supplied for research, diagnostic, and therapeutic applications.

-By Application: Research, Diagnostics and Therapeutics Drive Demand
Research applications include PCR, qPCR, sequencing, gene editing and molecular biology. Diagnostics use oligos in molecular assays and diagnostic kits, while therapeutics utilize modified oligonucleotides such as antisense oligos and siRNA candidates.

-By End User: Pharmaceutical & Biotechnology Companies Expand Utilization
Pharmaceutical and biotechnology companies use oligonucleotides for therapeutic development and manufacturing, while academic and research institutes primarily support molecular biology and discovery studies. Hospitals and diagnostic laboratories use synthesized oligos for clinical and molecular diagnostic workflows.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.